See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Natural Disasters
Baseball
Stock Markets
Military
Tariffs
UK Economy
Social Media
South America
Artificial Intelligence
Donald Trump
European Union
Property
Published • loading... • Updated

Heart failure patients benefit from dapagliflozin after TAVR procedure

Summary by News Medical
Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely to die or experience worsening heart failure at one year compared with patients who did not take the drug, according to a study presented at the American College of Cardiology's Annual Scientific Session.

5 Articles

All
Left
Center
2
Right
News MedicalNews Medical
Center

Heart failure patients benefit from dapagliflozin after TAVR procedure

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely to die or experience worsening heart failure at one year compared with patients who did not take the drug, according to a study presented at the American College of Cardiology's Annual Scientific Session.

·United States
Read Full Article
MedPage TodayMedPage Today
Reposted by
Anti-Aging, Acupuncture and Health NewsAnti-Aging, Acupuncture and Health News
Center

SGLT2i Improves Outcomes After TAVI

(MedPage Today) -- CHICAGO -- Dapagliflozin (Farxiga) lowered mortality and heart failure worsening in high-risk older adults getting transcatheter aortic valve implantation (TAVI), the DapaTAVI trial showed. In a population with a history of...

·New York, United States
Read Full Article
The Medical RepublicThe Medical Republic

Expanded PBS listing for empagliflozin - Medical Republic

The SGLT2 inhibitor is now subsidised for people at increased cardiovascular risk without the need for an unmet glycaemic target.

Read Full Article
Pharmacy TimesPharmacy Times

ACC 2025: Dapagliflozin Found Safe, Effective in Older Adults With Heart Failure Undergoing Valve Replacement

The DapaTAVI study is the first trial of a sodium-glucose cotransporter-2 (SGLT2) inhibitor for valvular disease.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Anti-Aging, Acupuncture and Health News broke the news in on Saturday, March 29, 2025.
Sources are mostly out of (0)

Similar News Topics

Disease

Disease

Medical

Medical

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal